Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer

Condition:   Bladder Cancer Intervention:   Drug: Pembrolizumab (MK-3475) Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials